ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ViiV

Related Keywords

United States ,Australia ,North Carolina ,Argentina ,Philadelphia ,Pennsylvania ,Washington ,South Africa ,Canada ,Russia ,London ,City Of ,United Kingdom ,Mexico ,Germany ,Middlesex ,United Kingdom General ,Italy ,Sweden ,Brentford ,Hounslow ,South Korea ,Spain ,France ,Lynn Baxter ,Josh Williams ,Jeff Mclaughlin ,Mick Readey ,Catherine Hartley ,Lyndsay Meyer ,Tim Foley ,Madeleine Breckon ,Evan Berland ,Turner Overton ,Kathleen Quinn ,Audrey Abernathy ,Kostenloser Wertpapierhandel ,James Dodwell ,Kristen Neese ,Nick Stone ,Glaxosmithkline ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,University Of Alabama At Birmingham ,Pfizer ,Company Annual Report On Form ,Shionogi Limited ,Pfizer Inc ,Viiv Healthcare Patient Assistance Program ,Department Of Medicine ,Janssen Sciences Ireland Unlimited Company ,Business Wire ,Viiv Healthcare ,Janssen Pharmaceutical Companies ,North America ,Intent To Treat Exposed ,Primary Investigator ,Safety Information ,Drug Reaction ,Systemic Symptoms ,Injection Reactions ,Adverse Reactions ,Virologic Response Due ,Drug Interactions ,Torsade De Pointes ,Acting Properties ,Potential Associated Risks ,Prescribing Information ,Patient Assistance Program ,Viiv Connect ,Annual Report ,England Wales ,West Road ,Reported Outcomes Through ,Trial Evaluating Long Acting Cabotegravir ,Rilpivirine Administered Every ,Lviiv ,Healthcare ,Nnounces ,Approval ,Cabenuva ,Cabotegravir ,Rilpivirine ,Very ,Months ,Xpanding ,Label ,First ,Only ,Omplete ,Song ,Acting ,Treatment ,